The largest study of the funding of cancer immunotherapy is published today (Friday).
The work of researchers who carried out the study include researchers affiliated with Dulal Focus, Tihsa Vetva Grèriale de Lille, the Institute of Classical Medicine (ICM) in Marseille and the Brussels Foundation, the Brussels Foundation for Innovation and Emerging Platform.
One of the main pillars of the research was to compare the funding amounts of the three entities. More specifically, the authors sought to compare funding while trying to draw conclusions on the effect of different entities on the use of hospital funds invested in cancer immunotherapy.
The results of the study, which is funded by the EU’s Horizon 2020 research and innovation program, showed that almost 40% of the 544 million euro that is guaranteed by the Horizon 2020 funding support is available to the three entities.
The next step will be to expand the work to confirm two main elements: the effect of different stages of funding and the impact of partial funding in the famous cancer industry.
In their paper on the study, the authors include both academic researchers and funders.
The work has been opened by the sector of biology, which includes the Institute of Cell Biology and Molecular Biology (ICBMB) and the Brussels Foundation. “The Institute of Cell Biology and Molecular Biology, the Brussels Foundation, and the Brussels Institute of Health and Welfare (BIH) are the main funding conditions for the RDOA,” explains the ICHB employee with expertise in public health finance.
The research, whose main aim was to prove that the funding amount is compatible with the known and potential usefulness of cancer immunotherapy, was financed by the EU’s Horizon 2020 funding. The authors were supported by ELLEACH, CRCHUM and CIBER. “The main funding mechanisms for the (…) ensembles of entities are the Horizon 2020′-linked Horizon 2020 funding, both in the initial and ongoing veins of the project, ” indicates the publication of this paper.
More research is needed.
These results “show that, in the long-term, providing more funding is a good way of promoting efficiency and quality of care for the patients referred to us via the formerly dedicated trauma department at the hospital Lausanne Zedinaer,” notes the paper.
“The most important message is that teaching the value of high-quality healthcare is a main pillar in the public health sphere,” concludes the article.